Objective:

To develop and validate a radiomics-based predictive model integrating clinical and imaging features to evaluate cervical lymph node response to I-131 therapy in differentiated thyroid cancer (DTC).

Approach:

Key Findings:

• The integrated clinical–radiomics model showed favorable discrimination in both training and validation cohorts, with specific metrics indicating model performance.
• The model demonstrated good calibration and net clinical benefit across relevant threshold probabilities.

Interpretation:

Limitations:

• External validation is required before routine clinical adoption.
• Comparison with existing predictive strategies is necessary.

Conclusion:

The proposed model provides a tool for supporting individualized management in DTC.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.